Across TCGA pan-cancer cohorts, MIR876 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIR876 data layer compared with 5 for mass-spec protein.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher MIR876 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR876 expression acts as an unfavorable survival marker.
OV are the cancer types where MIR876 Mutation most reproducibly stratifies survival.